Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?

Med Mal Infect. 2014 May;44(5):235-7. doi: 10.1016/j.medmal.2014.03.006. Epub 2014 Apr 26.
No abstract available

Keywords: Association bêta-lactamine/inhibiteur de bêta-lactamase; BLSE; Beta-lactam/beta-lactamase inhibitor combination; Bêta-lactamase à spectre étendu; ESBL-E; Extended-spectrum beta-lactamase.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / classification
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Proteins / metabolism*
  • Cross Infection / drug therapy
  • Cross Infection / epidemiology
  • Cross Infection / microbiology
  • Drug Resistance, Multiple, Bacterial
  • Enterobacteriaceae / drug effects*
  • Enterobacteriaceae / enzymology
  • Enterobacteriaceae / genetics
  • Enterobacteriaceae / isolation & purification
  • Enterobacteriaceae Infections / drug therapy*
  • Enterobacteriaceae Infections / epidemiology
  • Enterobacteriaceae Infections / microbiology
  • Female
  • France / epidemiology
  • Humans
  • Imipenem / pharmacology
  • Imipenem / therapeutic use
  • Intensive Care Units
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Retrospective Studies
  • Substrate Specificity
  • beta-Lactam Resistance / genetics*
  • beta-Lactamases / metabolism*
  • beta-Lactams / pharmacology
  • beta-Lactams / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • beta-Lactams
  • Imipenem
  • beta-Lactamases